Notice: Images are for illustration only and may not reflect the exact product you receive. Brand-name medications may look different depending on their country of origin—Canadian versions, for example, often include a "PR" symbol on the packaging. Rest assured, the medication, dosage, and active ingredients will be exactly as prescribed. Canada Pharmacy Store is committed to your health and safety, and we work only with licensed pharmacies to ensure you receive trusted, high-quality medication every time.
General Medication Fact Sheet for Venclexta
| Field | Information |
|---|---|
| Medication Name | Venclexta |
| Generic Name | Venetoclax |
| Boxed/Label Warning | Tumor Lysis Syndrome (TLS): Venclexta can cause rapid reduction in tumor size, resulting in TLS, which requires hospitalization for monitoring and management. |
| Purpose | Used to treat chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and acute myeloid leukemia (AML) in certain patients. |
| Mechanism of Action | A BCL-2 inhibitor, it binds directly to the BCL-2 protein, causing cancer cells to undergo apoptosis (cell death). |
| Dosage Forms | Oral tablets |
| Available Strengths | 10 mg, 50 mg, 100 mg |
| Dosage Frequency | Once daily |
| Common Side Effects | Neutropenia, diarrhea, nausea, anemia, thrombocytopenia, upper respiratory tract infection, fatigue. |
| Serious Side Effects | Tumor Lysis Syndrome (TLS), severe neutropenia, pneumonia, infections, bleeding. |
| Drug Interactions | Strong CYP3A inhibitors (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin), strong CYP3A inducers (e.g., rifampin, phenytoin, carbamazepine), grapefruit juice, P-gp and BCRP inhibitors. |
| Important Notes | Patients must be closely monitored for signs of TLS, especially during initial dose ramp-up. Prophylactic measures, such as hydration and allopurinol, are recommended to reduce the risk of TLS. Dosage adjustments may be necessary based on individual response and tolerability. |
| Storage | Store at room temperature between 68°F to 77°F (20°C to 25°C). Keep in the original container. |
| Missed Dose | If a dose is missed, take it as soon as possible unless it is almost time for the next dose. Do not double the dose. |
| Alternatives | Imbruvica (ibrutinib), Calquence (acalabrutinib), Rituxan (rituximab) + chemotherapy, Zydelig (idelalisib), Copiktra (duvelisib) |
Venclexta Alternatives
| Medication | Mechanism of Action | Notes |
|---|---|---|
| Imbruvica (ibrutinib) | Bruton’s tyrosine kinase (BTK) inhibitor | Used in CLL, SLL, and other B-cell malignancies. |
| Calquence (acalabrutinib) | Bruton’s tyrosine kinase (BTK) inhibitor | Another BTK inhibitor alternative for CLL/SLL. May have different side effect profile than Ibrutinib. |
| Rituxan (rituximab) + chemotherapy | Monoclonal antibody targeting CD20 + Various Chemotherapy agents | Chemoimmunotherapy regimens used in CLL/SLL. |
| Zydelig (idelalisib) | PI3K delta inhibitor | Another targeted therapy used in relapsed CLL/SLL. |
| Copiktra (duvelisib) | PI3K-delta and PI3K-gamma inhibitor | Used for relapsed or refractory CLL/SLL after at least two prior therapies. |
Venclexta Side Effects
| Common Side Effects | Serious Side Effects |
|---|---|
| Neutropenia | Tumor Lysis Syndrome (TLS) |
| Diarrhea | Severe Neutropenia |
| Nausea | Pneumonia |
| Anemia | Infections |
| Thrombocytopenia | Bleeding |
| Fatigue | Fever |
| Upper Respiratory Tract Infection | Kidney Problems |
Venclexta Dosage Guide
| Condition | Starting Dose | Maintenance Dose | Administration Notes |
|---|---|---|---|
| CLL/SLL (after prior therapy) | 20 mg once daily (Week 1) | 400 mg once daily | Follow a weekly ramp-up schedule (20mg -> 50mg -> 100mg -> 200mg -> 400mg) to minimize TLS risk. Take with food and water. |
| CLL/SLL (previously untreated) | 20 mg once daily (Week 1) | 400 mg once daily | Follow a weekly ramp-up schedule (20mg -> 50mg -> 100mg -> 200mg -> 400mg) to minimize TLS risk. Usually given in combination with Obinutuzumab. Take with food and water. |
| AML | 100 mg once daily (Day 1) | 400 mg once daily | Administered in combination with a hypomethylating agent (e.g., azacitidine or decitabine). Continue until disease progression or unacceptable toxicity. Take with food and water. |

